What is the expected growth forecast for the Non-Steroidal Anti-Inflammatory Drugs market?

The market is expected to grow at a CAGR of 6.1% from 2023 to 2028, driven by increasing demand.

What are the key drivers of the Non-Steroidal Anti-Inflammatory Drugs market?

Key drivers include rising prevalence of chronic pain and inflammation, and growing demand for over-the-counter medications.

What are the major challenges facing the Non-Steroidal Anti-Inflammatory Drugs market?

Challenges include increasing competition, stringent regulatory requirements, and potential side effects of NSAIDs.

Which regions are leading the Non-Steroidal Anti-Inflammatory Drugs market?

North America and Europe are leading the market, due to high demand and well-established healthcare infrastructure.

Who are the top companies in the Non-Steroidal Anti-Inflammatory Drugs market?

Top companies include Pfizer, Johnson & Johnson, and Bayer, which offer a range of NSAID products.

What future opportunities exist in the Non-Steroidal Anti-Inflammatory Drugs market?

Future opportunities include development of new formulations and delivery methods, and increasing demand from emerging markets.

How is technology impacting the Non-Steroidal Anti-Inflammatory Drugs market?

Technology is driving innovation in NSAID development, with advancements in pharmacogenomics and personalized medicine.

What is the current regulatory landscape for the Non-Steroidal Anti-Inflammatory Drugs market?

The regulatory landscape is stringent, with FDA and EMA guidelines governing NSAID approval, labeling, and safety monitoring.

What is the future outlook for the Non-Steroidal Anti-Inflammatory Drugs market?

The future outlook is positive, with growing demand and increasing investment in NSAID research and development.

Non-Steroidal Anti-Inflammatory Drugs Growth Trends & Opportunity Analysis 2033

Non-Steroidal Anti-Inflammatory Drugs by Application (Dental Pain, Muscle Aches, Pain caused by Gout, Bursitis, Menstrual Cramps, Fever, Others), by Types (Non-Selective NSAIDs, COX-2 Selective NSAIDs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Non-Steroidal Anti-Inflammatory Drugs Market Overview

The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market refers to the industry segment that deals with the development, manufacture, and distribution of non-steroidal anti-inflammatory medications. As a crucial part of the global pharmaceutical industry, the Non-Steroidal Anti-Inflammatory Drugs market size is expected to experience significant growth, driven by an increasing demand for effective pain management solutions. The growth outlook for the NSAIDs market is promising, with a projected market forecast that indicates a steady expansion of the industry. The industry expansion is anticipated to be driven by factors such as an aging population, an increase in chronic pain cases, and a growing awareness of the benefits of NSAIDs.

Loading chart…

The current Non-Steroidal Anti-Inflammatory Drugs market size is estimated to be around $15.6 billion. The market is expected to grow at a CAGR of 5-6% during the forecast period, driven by macro drivers such as an increasing prevalence of chronic pain and inflammation. Key forces shaping the industry include technology shifts towards more targeted and effective treatments, regulations aimed at ensuring the safe use of NSAIDs, and consumer behavior trends that prioritize health and wellness. The largest region for the NSAIDs market is North America, while the fastest-growing region is expected to be the Asia-Pacific region, driven by an increasing demand for pharmaceuticals and healthcare services.

Report Overview

Report Attribute	Details
Market size value in 2025	123.40 million
Revenue forecast in 2033	231.81 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Bayer AG; GSK plc; Dr. Reddy’s Laboratories Ltd; Viatris Inc; Teva Pharmaceutical Industries Ltd.; Johnson And Johnson Services, Inc.; Merck & Co., Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Non-Steroidal Anti-Inflammatory Drugs market is poised for significant growth, driven by a combination of factors that are shaping its dynamics. Understanding these market dynamics is crucial for stakeholders to navigate the landscape effectively and capitalize on emerging opportunities.

Growth Drivers2 items

Increasing prevalence of chronic pain and inflammatory diseases is driving the demand for Non-Steroidal Anti-Inflammatory Drugs, thereby contributing to the growth of the market size. This trend is particularly pronounced in aging populations where the incidence of such conditions is higher.

Advancements in drug formulation technologies have led to the development of more effective and safer Non-Steroidal Anti-Inflammatory Drugs, enhancing their adoption and contributing to a positive growth forecast for the market.

Restraints2 items

The Non-Steroidal Anti-Inflammatory Drugs market faces restraints due to stringent regulatory requirements and the need for extensive clinical trials, which can delay the launch of new products and impact the overall market size. These regulatory hurdles can be particularly challenging for smaller pharmaceutical companies.

Side effects associated with Non-Steroidal Anti-Inflammatory Drugs, such as gastrointestinal issues, can limit their use and affect market growth. The risk of adverse effects is a critical consideration in the development and prescription of these drugs.

Opportunities2 items

Emerging markets present significant opportunities for the Non-Steroidal Anti-Inflammatory Drugs market, driven by increasing healthcare expenditure and a growing awareness of available treatments. Companies can capitalize on these trends to expand their market share.

The development of novel, targeted therapies with improved safety profiles offers opportunities for innovation and growth in the Non-Steroidal Anti-Inflammatory Drugs market, potentially leading to an increased market size and a more favorable growth forecast.

Challenges2 items

Generic competition poses a significant challenge to the Non-Steroidal Anti-Inflammatory Drugs market, as it can lead to price erosion and reduced revenue for pharmaceutical companies. Managing this challenge is crucial for maintaining profitability.

The Non-Steroidal Anti-Inflammatory Drugs market must also contend with challenges related to sustainability and environmental impact, as the production and disposal of these drugs can have negative environmental consequences, affecting the market's long-term viability.

Market Segmentation

Loading chart…

The Application segment of the Non-Steroidal Anti-Inflammatory Drugs market refers to the various therapeutic areas where these drugs are utilized. This includes pain management, inflammatory diseases, and fever reduction. Understanding the Non-Steroidal Anti-Inflammatory Drugs segmentation is crucial for industry players to identify areas of growth and development. The application segment contributes significantly to the overall market size, as it encompasses a wide range of uses across different medical specialties.

The Types segment of the Non-Steroidal Anti-Inflammatory Drugs market is categorized into subtypes, including ibuprofen, naproxen, aspirin, and celecoxib. Each subtype has its unique characteristics, indications, and market share. Analyzing the market taxonomy of Non-Steroidal Anti-Inflammatory Drugs is essential to comprehend the competitive landscape and identify opportunities for innovation and expansion. The types segment plays a vital role in determining the overall market size, as it directly impacts the revenue generated by each subtype.

Non-Steroidal Anti-Inflammatory Drugs Segmentation Breakdown11 items

Application

Dental Pain

Muscle Aches

Pain caused by Gout

Bursitis

Menstrual Cramps

Fever

Others

Types

Non-Selective NSAIDs

COX-2 Selective NSAIDs

Regional Insights

Loading chart…

The Non-Steroidal Anti-Inflammatory Drugs market growth is expected to vary across regions, with Asia Pacific being the largest region and Latin America being the fastest-growing region. Key drivers for North America include increasing adoption of over-the-counter NSAIDs, policies supporting generic drug development, and significant investments in research and development.

In Europe, key drivers include a mature ecosystem, high demographics of aging population, and favorable infrastructure for pharmaceutical manufacturing. Asia Pacific is driven by large demographics, increasing adoption of modern healthcare, and significant investments in pharmaceutical infrastructure. Latin America is driven by increasing adoption of generic drugs, favorable policies, and growing infrastructure for pharmaceutical manufacturing.

The Middle East & Africa region is driven by increasing adoption of modern healthcare, significant investments in pharmaceutical infrastructure, and growing demographics. The regional forecast indicates a significant Non-Steroidal Anti-Inflammatory Drugs market growth in Asia Pacific and Latin America, driven by increasing demand for NSAIDs and favorable market conditions.

Competitive Landscape

The Non-Steroidal Anti-Inflammatory Drugs market exhibits a moderately consolidated structure, driven by both global players and local/regional companies. The Non-Steroidal Anti-Inflammatory Drugs competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies to gain market share.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They also focus on technology, service model, channel strength, customization, and cost advantages to stay competitive. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategic focuses:

Pfizer Inc. regional expansion

Bayer AG innovation pipeline

GSK plc premium pricing

Dr. Reddy’s Laboratories Ltd local manufacturing

Viatris Inc OEM tie-ups

Teva Pharmaceutical Industries Ltd vertical integration

Key Non-Steroidal Anti-Inflammatory Drugs Companies8 items

Pfizer Inc.

Bayer AG

GSK plc

Dr. Reddy’s Laboratories Ltd

Viatris Inc

Teva Pharmaceutical Industries Ltd.

Johnson And Johnson Services, Inc.

Merck & Co., Inc.

Market Ecosystem

The Non-Steroidal Anti-Inflammatory Drugs ecosystem encompasses a complex network of participants, from upstream technology providers and raw material suppliers to midstream manufacturers and downstream distributors, channels, and end users. Value is created and captured through the development, production, and distribution of these drugs, with each participant playing a distinct role in the overall value chain analysis.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Non-Steroidal Anti-Inflammatory Drugs

Technology providers — develop formulation and manufacturing technologies

Distributors / channel partners — deliver products to pharmacies and hospitals

Regulators/standards bodies — oversee safety and efficacy standards

Service providers / after-sales — offer patient support and education services

End users / buyers — purchase and administer Non-Steroidal Anti-Inflammatory Drugs

Within the Non-Steroidal Anti-Inflammatory Drugs ecosystem, control points are primarily held by regulators and manufacturers, who influence adoption through safety and efficacy standards, and product development, respectively. Dependency risks arise from input constraints, such as active pharmaceutical ingredient availability, and standards approvals, which can impact production and distribution. Switching costs and partnerships between manufacturers and distributors can also affect the ecosystem, while regional differences in regulatory frameworks and healthcare systems may lead to variations in the ecosystem's structure and dynamics.

Recent Industry Insights

The Non-Steroidal Anti-Inflammatory Drugs industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have driven innovation in the field. Notable mergers and acquisitions have also led to market consolidation, with major players expanding their product portfolios. Furthermore, several product launches have taken place, featuring advanced formulations and delivery systems. Regulatory changes, including updated guidelines for clinical trials, have also impacted the industry. A shift in consumer trends towards more natural and sustainable treatment options has been observed, with companies responding by investing in research and development of new compounds.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Non-Steroidal Anti-Inflammatory Drugs market. The market attractiveness is moderate, driven by the increasing prevalence of chronic pain and inflammation. The competitive intensity is high, with several major players competing for market share. Looking ahead, the long-term Non-Steroidal Anti-Inflammatory Drugs market outlook is promising, with opportunities for innovation in topical and injectable formulations.

The innovation landscape is evolving, with a focus on developing safer and more effective treatments. However, the demand–supply balance is a key concern, with fluctuations in demand driven by changing patient needs and preferences. Key risk factors include regulatory challenges, patent expirations, and increasing competition from alternative therapies. Overall, the market requires a nuanced understanding of these factors to navigate successfully.

11 items

1. Executive Summary

2. Non-Steroidal Anti-Inflammatory Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Non-Steroidal Anti-Inflammatory Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Non-Steroidal Anti-Inflammatory Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Dental Pain

6.1.2. Muscle Aches

6.1.3. Pain caused by Gout

6.1.4. Bursitis

6.1.5. Menstrual Cramps

6.1.6. Fever

6.1.7. Others

6.2. Global Non-Steroidal Anti-Inflammatory Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Non-Selective NSAIDs

6.2.2. COX-2 Selective NSAIDs

6.3. Global Non-Steroidal Anti-Inflammatory Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Non-Steroidal Anti-Inflammatory Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Non-Steroidal Anti-Inflammatory Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Non-Steroidal Anti-Inflammatory Drugs Market Competition by Key Manufacturers

8.1. Global Non-Steroidal Anti-Inflammatory Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Non-Steroidal Anti-Inflammatory Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GSK plc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Dr. Reddy’s Laboratories Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Viatris Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Teva Pharmaceutical Industries Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Johnson And Johnson Services, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck & Co., Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Non-Steroidal Anti-Inflammatory Drugs Market

Figure 4: Global Non-Steroidal Anti-Inflammatory Drugs Market: Drivers

Figure 5: Global Non-Steroidal Anti-Inflammatory Drugs Market: Challenges

Figure 6: Global Non-Steroidal Anti-Inflammatory Drugs Market: Trends

Figure 7: Global Non-Steroidal Anti-Inflammatory Drugs Market: Opportunity

Figure 8: Global Non-Steroidal Anti-Inflammatory Drugs Market: Restraint

Figure 9: Global Non-Steroidal Anti-Inflammatory Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Non-Steroidal Anti-Inflammatory Drugs Market Value (USD Million) By Region

Figure 15: Global Non-Steroidal Anti-Inflammatory Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Non-Steroidal Anti-Inflammatory Drugs Market Value (USD Million) By Region

Figure 23: Global Non-Steroidal Anti-Inflammatory Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Non-Steroidal Anti-Inflammatory Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Non-Steroidal Anti-Inflammatory Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Non-Steroidal Anti-Inflammatory Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Non-Steroidal Anti-Inflammatory Drugs Market Value (USD Million) By Region

Table 10: Global Non-Steroidal Anti-Inflammatory Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Non-Steroidal Anti-Inflammatory Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Non-Steroidal Anti-Inflammatory Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Non-Steroidal Anti-Inflammatory Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Inc. Basic Information And Sales Area

Table 31: Pfizer Inc.. Products Portfolio

Table 32: Bayer AG Basic Information And Sales Area

Table 33: Bayer AG. Products Portfolio

Table 34: GSK plc Basic Information And Sales Area

Table 35: GSK plc. Products Portfolio

Table 36: Dr. Reddy’s Laboratories Ltd Basic Information And Sales Area

Table 37: Dr. Reddy’s Laboratories Ltd. Products Portfolio

Table 38: Viatris Inc Basic Information And Sales Area

Table 39: Viatris Inc. Products Portfolio

Table 40: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 41: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 42: Johnson And Johnson Services, Inc. Basic Information And Sales Area

Table 43: Johnson And Johnson Services, Inc.. Products Portfolio

Table 44: Merck & Co., Inc. Basic Information And Sales Area

Table 45: Merck & Co., Inc.. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Non-Steroidal Anti-Inflammatory Drugs Market Value (USD Million) By Region

Table 51: Global Non-Steroidal Anti-Inflammatory Drugs Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Non-Steroidal Anti-Inflammatory Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	123.40 million
Revenue forecast in 2033	231.81 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Bayer AG; GSK plc; Dr. Reddy’s Laboratories Ltd; Viatris Inc; Teva Pharmaceutical Industries Ltd.; Johnson And Johnson Services, Inc.; Merck & Co., Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Non-Steroidal Anti-Inflammatory Drugs Segmentation Breakdown11 items

Application

Dental Pain

Muscle Aches

Pain caused by Gout

Bursitis

Menstrual Cramps

Fever

Others

Types

Non-Selective NSAIDs

COX-2 Selective NSAIDs

Regional Insights

Loading chart…

Competitive Landscape

Pfizer Inc. regional expansion

Bayer AG innovation pipeline

GSK plc premium pricing

Dr. Reddy’s Laboratories Ltd local manufacturing

Viatris Inc OEM tie-ups

Teva Pharmaceutical Industries Ltd vertical integration

Key Non-Steroidal Anti-Inflammatory Drugs Companies8 items

Pfizer Inc.

Bayer AG

GSK plc

Dr. Reddy’s Laboratories Ltd

Viatris Inc

Teva Pharmaceutical Industries Ltd.

Johnson And Johnson Services, Inc.

Merck & Co., Inc.

Market Ecosystem

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Non-Steroidal Anti-Inflammatory Drugs

Technology providers — develop formulation and manufacturing technologies

Distributors / channel partners — deliver products to pharmacies and hospitals

Regulators/standards bodies — oversee safety and efficacy standards

Service providers / after-sales — offer patient support and education services

End users / buyers — purchase and administer Non-Steroidal Anti-Inflammatory Drugs

Recent Industry Insights

Analyst Overview

Table of Contents